07:33 AM EDT, 04/15/2024 (MT Newswires) -- Neumora Therapeutics ( NMRA ) said Monday that the US Food and Drug Administration has placed a clinical hold on the phase 1 trial of its NMRA-266 potential brain disease treatment after the emergence of pre-clinical data showing convulsions in rabbits.

The phase 1 study involves 30 participants with no evidence of convulsions observed, Neumora said, adding it was discussing the next steps with the FDA to resolve the clinical hold.

During the talks, Neumora said its prior guidance on NMRA-266 is no longer applicable. NMRA-266 is a positive allosteric modulator of the M4 muscarinic receptor and is part of the company's M4 PAM franchise, Neumora added.